Literature DB >> 12354285

Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics.

Sharon Miksys1, Yushu Rao, Ewa Hoffmann, Deborah C Mash, Rachel F Tyndale.   

Abstract

Cytochrome P450 (CYP) 2D6 is expressed in liver, brain and other extrahepatic tissues where it metabolizes a range of centrally acting drugs and toxins. As ethanol can induce CYP2D in rat brain, we hypothesized that CYP2D6 expression is higher in brains of human alcoholics. We examined regional and cellular expression of CYP2D6 mRNA and protein by RT-PCR, Southern blotting, slot blotting, immunoblotting and immunocytochemistry. A significant correlation was found between mean mRNA and CYP2D6 protein levels across 13 brain regions. Higher expression was detected in 13 brain regions of alcoholics (n = 8) compared to nonalcoholics (n = 5) (anovap < 0.0001). In hippocampus this was localized in CA1-3 pyramidal cells and dentate gyrus granular neurons. In cerebellum this was localized in Purkinje cells and their dendrites. Both of these brain regions, and these same cell-types, are known to be susceptible to alcohol damage. For one case, a poor metabolizer (CYP2D6*4/*4), there was no detectable CYP2D6 protein, confirming the specificity of the antibody used. These data suggest that in alcoholics elevated brain CYP2D6 expression may contribute to altered sensitivity to centrally acting drugs and to the mediation of neurotoxic and behavioral effects of alcohol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354285     DOI: 10.1046/j.1471-4159.2002.01069.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

2.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

3.  mRNA distribution and heterologous expression of orphan cytochrome P450 20A1.

Authors:  Katarina Stark; Zhong-Liu Wu; Cheryl J Bartleson; F Peter Guengerich
Journal:  Drug Metab Dispos       Date:  2008-06-09       Impact factor: 3.922

Review 4.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

5.  First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo.

Authors:  Kaidi Zhou; Jibran Y Khokhar; Bin Zhao; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2013-04-23       Impact factor: 5.858

6.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 7.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

8.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

9.  The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

Authors:  Natasha T Snider; Matthew J Sikora; Chitra Sridar; Thomas J Feuerstein; James M Rae; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-12       Impact factor: 4.030

10.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

Authors:  Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.